IRLAB Therapeutics AB Class A (SE:IRLAB.A)
:IRLAB.A
Top Page
IRLAB Therapeutics AB Class A
(IRLAB.A)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr1.50
▼(-25.37% Downside)
Action:ReiteratedDate:03/03/26
The score is held down primarily by weak financial performance—multi-year losses and continued cash burn with shrinking equity—followed by bearish technicals as the stock trades below key moving averages with negative MACD. Valuation offers limited support because losses drive a negative P/E and no dividend yield is available.
Positive Factors
Focused CNS drug development pipeline
A concentrated R&D focus on CNS disorders and Parkinson’s creates durable domain expertise and technical know-how. This specialization raises entry barriers, supports targeted partnerships and licensing, and increases the odds that clinical progress translates into valuable collaboration or milestone revenue over months.
Negative Factors
Persistent multi-year losses and negative margins
Sustained negative margins indicate the core operations are not covering costs and that profitability is distant. This structural deficit makes the company reliant on external capital or partnerships, raising dilution and execution risk if clinical progress is slower than planned.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused CNS drug development pipeline
A concentrated R&D focus on CNS disorders and Parkinson’s creates durable domain expertise and technical know-how. This specialization raises entry barriers, supports targeted partnerships and licensing, and increases the odds that clinical progress translates into valuable collaboration or milestone revenue over months.
Read all positive factors
IRLAB Therapeutics AB Class A (IRLAB.A) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr121.63M
Dividend YieldN/A
Average Volume (3M)244.46K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth69.03%
EPS Growth23.10%
CountrySE
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.29
Shares Outstanding84,858,246
10 Day Avg. Volume145,848
30 Day Avg. Volume244,458
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)4.30
Price to Sales (P/S)2.30
P/FCF Ratio-2.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.62
Revenue Forecast (FY)kr108.80M
IRLAB Therapeutics AB Class A Business Overview & Revenue Model
Company Description
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial fo...
How the Company Makes Money
IRLAB Therapeutics primarily makes money through business development arrangements typical for clinical-stage biotech companies: (1) upfront payments received when entering licensing or collaboration agreements for its drug candidates or technolog...
IRLAB Therapeutics AB Class A Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 57.46M | 94.63M | 5.68M | 61.14M | 207.78M |
| Gross Profit | -92.35M | -92.42M | -122.73M | -111.23M | 168.69M |
| EBITDA | -88.03M | -68.07M | -173.32M | -109.13M | 55.79M |
| Net Income | -110.01M | -83.13M | -177.84M | -114.20M | 51.78M |
Balance Sheet | |||||
| Total Assets | 138.21M | 136.21M | 177.12M | 323.56M | 472.45M |
| Cash, Cash Equivalents and Short-Term Investments | 81.86M | 66.92M | 111.31M | 252.78M | 401.90M |
| Total Debt | 29.95M | 60.42M | 27.57M | 3.98M | 6.60M |
| Total Liabilities | 107.49M | 103.58M | 61.36M | 32.72M | 72.97M |
| Stockholders Equity | 30.72M | 32.63M | 115.76M | 290.83M | 399.48M |
Cash Flow | |||||
| Free Cash Flow | -55.22M | -65.79M | -165.14M | -145.99M | 127.93M |
| Operating Cash Flow | -55.22M | -65.59M | -164.85M | -142.61M | 128.64M |
| Investing Cash Flow | 0.00 | -199.00K | -293.00K | -3.38M | -708.00K |
| Financing Cash Flow | 73.41M | 21.40M | 23.68M | -3.13M | -3.04M |
IRLAB Therapeutics AB Class A Technical Analysis
Negative
2.01
Price Trends
1.67
Negative
1.88
Negative
2.54
Negative
Market Momentum
-0.06
Positive
33.56
Neutral
31.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IRLAB.A, the sentiment is Negative. The current price of 2.01 is above the 20-day moving average (MA) of 1.56, above the 50-day MA of 1.67, and below the 200-day MA of 2.54, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 33.56 is Neutral, neither overbought nor oversold. The STOCH value of 31.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IRLAB.A.
IRLAB Therapeutics AB Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr221.10M | -9.08 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr191.15M | -2.92 | -51.35% | ― | ― | -34.02% | |
48 Neutral | kr264.03M | -13.67 | -59.78% | ― | ― | 52.96% | |
47 Neutral | kr218.00M | -1.66 | -1291.15% | ― | ― | 28.54% | |
43 Neutral | kr121.63M | -1.72 | -199.86% | ― | 69.03% | 23.10% | |
41 Neutral | kr219.62M | -4.03 | ― | ― | -7.68% | 17.93% |
* Healthcare Sector Average
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.43
-5.29
-78.69%
SE:ISOFOL
Isofol Medical AB
0.68
-1.04
-60.47%
SE:XINT
Xintela AB
0.26
-0.12
-32.36%
SE:ELIC
Elicera Therapeutics AB
5.44
2.52
86.30%
SE:ACTI
Active Biotech AB
0.08
0.03
43.86%
SE:INIT
Initiator Pharma A/S
3.23
-2.77
-46.17%
IRLAB Therapeutics AB Class A Corporate Events
IRLAB Showcases Parkinson’s Pipeline and AI Discovery Advances at AD/PD 2026
Mar 17, 2026
IRLAB Therapeutics will present new clinical and preclinical data at the AD/PD 2026 conference in Copenhagen, highlighting progress across its Parkinson’s disease pipeline and discovery platform. The company will showcase phase IIb data for ...
IRLAB to Showcase Parkinson’s Pipeline at Gothenburg Life Science Day
Mar 2, 2026
IRLAB Therapeutics AB, a Swedish biotech specializing in innovative Parkinson’s disease therapies, is advancing a diversified pipeline that spans late-stage candidates for levodopa-induced dyskinesias and fall reduction, as well as earlier-s...
IRLAB Triggers USD 3 Million Milestone as First Patient Dosed in IRL757 Parkinson’s Apathy Trial
Feb 26, 2026
IRLAB Therapeutics has dosed the first patient in its Phase Ib LIFT-PD trial of IRL757, a potential treatment for apathy in Parkinson’s disease, triggering a USD 3 million milestone payment from its development partner, the McQuade Center fo...
IRLAB Advances CNS Pipeline as 2025 Loss Widens and Cash Position Strengthens
Feb 25, 2026
IRLAB Therapeutics reported full-year 2025 results showing net sales of SEK 57.5 million, a widened operating loss of SEK 93.4 million and year-end cash of SEK 81.9 million, while maintaining an average of 31 employees and seeing its share price d...
IRLAB Wins Expert Backing to Advance Parkinson’s Drug Pirepemat After Positive Phase IIb Signals
Feb 20, 2026
IRLAB Therapeutics has received unanimous backing from its scientific advisory board to proceed with development of its Parkinson’s candidate pirepemat, after experts judged the pharmacological rationale sound and the reduction in falls seen...
IRLAB to Webcast Year-End 2025 Results as Parkinson’s Pipeline Advances
Feb 18, 2026
IRLAB Therapeutics AB, a Nasdaq Stockholm-listed biopharmaceutical developer of novel Parkinson’s disease treatments, will publish its year-end 2025 report on February 25, 2026, at 07:00 CET. The Gothenburg-based company, led by CEO Kristina...
IRLAB partners with Denmark’s Biomia to apply AI-driven ISP platform to CNS drug candidates
Jan 19, 2026
IRLAB Therapeutics has entered a collaboration with Danish biotech firm Biomia ApS to apply IRLAB’s Integrative Screening Process (ISP) platform to Biomia’s small-molecule drug candidates targeting undisclosed central nervous system in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.